Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Bielack, Stefan; Carrle, Dorothe; Casali, Paolo G.

doi:10.1093/annonc/mdp154

Cited by 210 publications

(169 citation statements)

References 19 publications

Supporting

Mentioning

159

Contrasting

Unclassified

Order By: Relevance

“…Similarly, our finding that more than 70% of OS occurred in the distal femur and proximal tibia is consistent with previous studies (27)(28)(29). Surgical tumor resection (100%) and (neo)-adjuvant chemotherapy (93%) were identified as the main therapeutic strategies, substantiating the modern therapy regimen (30,31). The mean age of patients with ES was 28.8±9.7 years (range=16-44 years), and was higher than proposed by previous authors for skeletal manifestations (27,32).…”

Section: Psychosocial Distress Levels In Patients With Osteosarcomasupporting

confidence: 92%

IT-based Psychosocial Distress Screening in Patients with Sarcoma and Parental Caregivers via Disease-specific Online Social Media Communities

Pohlig

Lenze

Mühlhofer

et al. 2017

View full text Add to dashboard Cite

Section: Psychosocial Distress Levels In Patients With Osteosarcomasupporting

confidence: 92%

IT-based Psychosocial Distress Screening in Patients with Sarcoma and Parental Caregivers via Disease-specific Online Social Media Communities

Pohlig

Lenze

Mühlhofer

et al. 2017

View full text Add to dashboard Cite

“…1 Current standard treatment regimens consist of surgery and polychemotherapy. Unfortunately, despite multimodal treatment the final outcome has not improved significantly during the last decade and severe side effects of intensive chemotherapy treatment schedules are observed frequently.…”

mentioning

confidence: 99%

Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models

et al. 2014

View full text Add to dashboard Cite

Mammalian target of rapamycin (mTOR) is a new promising oncological target. However, most clinical studies reported only modest antitumor activity during mTOR-targeted monotherapies, including studies in osteosarcomas, emphasizing a need for improvement. We hypothesized that the combination with rationally selected other therapeutic agents may improve response. In this study, we examined the efficacy of the mTOR inhibitor temsirolimus combined with cisplatin or bevacizumab on the growth of human osteosarcoma xenografts (OS-33 and OS-1) in vivo, incorporating functional imaging techniques and microscopic analyses to unravel mechanisms of response. In both OS-33 and OS-1 models, the activity of temsirolimus was significantly enhanced by the addition of cisplatin (TC) or bevacizumab (TB). Extensive immunohistochemical analysis demonstrated apparent effects on tumor architecture, vasculature, apoptosis and the mTOR-pathway with combined treatments. Osteosarcoma is the most commonly diagnosed primary malignant tumor of the bone mainly affecting children and adolescents. 1 Current standard treatment regimens consist of surgery and polychemotherapy. Unfortunately, despite multimodal treatment the final outcome has not improved significantly during the last decade and severe side effects of intensive chemotherapy treatment schedules are observed frequently. On top of that, research on targeted treatments in osteosarcomas lags behind. This underscores the absolute need for novel, targeted therapies to treat these often young patients.Blocking of mammalian target of rapamycin (mTOR) signaling emerged as a promising approach to target osteosarcomas. mTOR, also known as sirolimus effector protein, is an intracellular serine/threonine kinase involved in the phosphatidylinositol 3-kinase (PI3K)/Akt signaling cascade and signals downstream of several receptor tyrosine kinases (RTKs), including but not limited to the insulin-like growth factor 1

show abstract

“…[5][6][7][8] En la serie de la Clínica Mayo, se revisaron 1952 osteosarcomas hasta 2010 y sólo 61 de ellos tuvieron como precursor la enfermedad de Paget; y explica el 27,5% de todos los tumores óseos malignos y el 19,2% de todos los tumores óseos. Es el tumor más común, si se excluyen los mielomas.…”

Section: Discussionunclassified

“…Es infrecuente su presentación en niños <6 años y adultos >60 años; sin embargo, encontramos dos pacientes en cada uno de estos dos grupos. [16][17][18][19][21][22][23]25 En el osteosarcoma, la relación hombre:mujer es aproximadamente de 1,4:1 a 1,5:1, con leve predominio en los varones, [4][5][6]12 lo que se vio ligeramente más acentuado (1,56:1). [21][22][23] El osteosarcoma aparece principalmente en las regiones yuxtaepifisarias de crecimiento rápido de huesos largos en el 80-90% de los casos.…”

Section: Discussionunclassified

Comportamiento epidemiológico del osteosarcoma en la población mexicana entre 2005 y 2014. [Epidemiologic behavior of osteosarcoma in Mexican population from 2005 to 2014].

Rodríguez-Franco

Gómez

Zepeda³

et al. 2016

Rev. Asoc. Arg. Ort. y Traumatol

View full text Add to dashboard Cite

ResumenIntroducción: El osteosarcoma representa el 15% de las neoplasias óseas. En México, constituye el 4,5% de las neoplasias y el 46,6-74% de los tumores óseos malignos, con ligero predominio en los varones adolescentes y el 50-80% en rodilla y húmero proximal. Objetivo: Identificar la distribución, la frecuencia relativa y la tendencia del osteosarcoma y su proyección a cinco años. Materiales y Métodos: Estudio epidemiológico, de registro de pacientes con diagnóstico histológico de osteosarcoma entre 2005 y 2014. Se analizaron los siguientes datos: edad, sexo, diagnóstico, localización, lado y estadio con estadística descriptiva y dispersión.Los resultados se sometieron a análisis mediante el índice de Pearson y regresión lineal por mé-todo de mínimos cuadrados. Resultados: Se analizaron 4744 casos. La incidencia de osteosarcoma fue del 3,29% y constituyó el 56,2% de los tumores óseos malignos primarios. La edad de los pacientes era 18.6 ± 16.8 años, con mayor incidencia en la segunda década de la vida (54,1%); la relación hombre:mujer era de 1,64:1. El 55,8% comprometía la rodilla, seguida del húmero proximal (7,1%). La variedad histológica predominante fue osteoblástica (76,9%). El estadio IIB fue más frecuente (77,6%), seguido del IIIB (13,8%). A los cinco años, se predice un aumento en la incidencia de osteosarcoma. Conclusiones: Esta es la mayor serie de osteosarcoma en América Latina. Se predice un incremento en la incidencia de osteosarcoma. Es necesario identificar factores de riesgo para establecer este comportamiento particular. Results: We analyzed 4,744 cases. Osteosarcoma had a frequency of 3.29% and it accounted for 56.2% of primary malignant bone tumors. Patients´ age was 18.6 ± 16.8 years old with higher incidence in the second decade of life (54.1%); men to women ratio was 1.64:1. Osteosarcoma affected the knee in 55.8% of the cases, followed by the proximal humerus (7.1%). Predominant histologic subtype was osteoblastic (76.9%). IIB stage was more frequent (77.6%), followed by IIIB (13.8%). To five years, an increased incidence of osteosarcoma is predicted. Conclusions: This is the largest case series of osteosarcoma in Latin America. A rising incidence of osteosarcoma is predicted. It is necessary to identify risk factors to establish this particular behavior.

show abstract

Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Cited by 210 publications

References 19 publications

IT-based Psychosocial Distress Screening in Patients with Sarcoma and Parental Caregivers via Disease-specific Online Social Media Communities

IT-based Psychosocial Distress Screening in Patients with Sarcoma and Parental Caregivers via Disease-specific Online Social Media Communities

Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models

Comportamiento epidemiológico del osteosarcoma en la población mexicana entre 2005 y 2014. [Epidemiologic behavior of osteosarcoma in Mexican population from 2005 to 2014].

Contact Info

Product

Resources

About